NASDAQ
3.41USD
+0.01 (+0.29%)
We have scored 6 news catalysts on SeaStar Medical Holding Corporation (ICU) over the past 12 months. The biggest single-day move next to one of them came Mar 9, 2026, when ICU closed +4.8%: “SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th”. Coverage across the window leans positive (average ticker sentiment +0.65). Most of the impact sits in sector healthcare and pricing power structural.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9.7M
P/E
—
EPS
—
Beta
-1.03
52W range
2.07-7.35
Day range
3.30–3.41
Open
3.40
Prev close
3.40
Volume
2.2K
Avg volume
76.5K
Dividend
0.00
IPO
2021-03-18
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about SeaStar Medical Holding Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ICU: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
